The Research and Evaluation Group has released a report on Texas pharmacy closed formulary outcomes. This study looks at injured employee outcomes such as return-to-work rates and health outcomes since the formulary was implemented.
Need just the key findings? Check the TDI website for our new snapshot tool on the pharmacy formulary report.
**Review and Dispute activities start on April 1st and can continue until end of the calendar year**
CALL FOR CASE STUDIES: The Texas Pain Society invites members and others to submit case studies to be considered for presentation at the 11th Annual Scientific Meeting.
The call for case study is open to Texas fellows and residents in a pain fellowship. Entries must be received before the cutoff date. All submissions will be reviewed by the committee and the top 5 submissions will be asked to present live at the TPS 11th Annual Scientific Meeting in October.
2019 Winners!
“Care must be a patient-centered experience. We need to treat people with compassion, and emphasize personalized care tailored to the specific circumstances and unique needs of each patient,” said Adm. Brett P. Giroir, M.D., assistant secretary for health. “This Guide provides more resources for clinicians to best help patients achieve the dual goals of effective pain management and reduction in the risk for addiction.”
The Samuel J. Hassenbusch, MD, PhD Continued Learning Scholarships are annual scholarships sponsored by the Texas Pain Society & Texas Pain Foundation and created to honor the memory of TPS Board Member, Dr. Sam Hassenbusch.
Dr. Hassenbusch was an advocate for teaching and spent a majority of his life teaching others what he had learned.
Hassenbusch Continued Learning Case Study Presentations
CALL FOR CASE STUDIES: The Texas Pain Society invites members and others to submit case studies to be considered for presentation at the 11th Annual Scientific Meeting.
Texas Medical Association
By Joey Berlin
September 12, 2019
In the opinion, Attorney General Ken Paxton addressed three questions from Sherif Zaafran, MD, president of the Texas Medical Board (TMB):
Schade Hill ‐ Public Policy Pain Champion Award - Representative JD Sheffield, MD
Dr. J.D. Sheffield was elected to the Texas House of Representatives in 2012 to serve the citizens of Texas House District 59, which includes Comanche, Coryell, Erath, Hamilton, McCulloch, Mills, San Saba, and Somervell Counties. He was re-elected to his 4th term in the 2018 March Primary.
Dr. Sheffield has been practicing family medicine in and around Gatesville for over 25 years. As the only rural physician in the Texas Legislature, Dr. Sheffield has been honored to serve on the House Public Health Committee for all three terms, and currently serves as Vice-Chairman.
September 6, 2019 marked another successful year of partnership between Texas Pain Society & Texas Society of Anesthesiologist!
Each year TPS presents a 3 hour parallel session regarding pain medicine during the TSA Annual Conference.
This year we had Drs. Max Eckmann, C.M. Schade and Dhanalakshmi Koyyalagunta, MD representing TPS and an interactive crowd that was very engaged in the current standards and best practices for treating chronic pain patients.
Attorney General Ken Paxton Issues Statement on Chapter 11
Bankruptcy Filing of Purdue Pharma
Description:
The Texas Prescription Monitoring Program (PMP) helps health professionals make decisions about prescribing and dispensing and can be used to improve patient health. Four experts will share their knowledge about the Texas PMP, enhancements to the system, and new tools available to help you feel confident about sending someone home with opioids.
Learning Objectives:
1.5 Continuing Education Credits/Contact Hours Available for the Following (live* event only):
Thanks in part to the new state law, it’s still confusing and includes a somewhat larger group of patients – all patients with epilepsy as well as those with seizure disorders, multiple sclerosis, spasticity, amyotrophic lateral sclerosis (ALS), autism, terminal cancer, and incurable neurodegenerative diseases.
Confusion has been fueled by another 2019 measure: House Bill 1325 legalized the production and sale of hemp and some products derived from hemp that have high levels of CBD, which is non-euphoric and has low levels of tetrahydrocannabinol (or THC), the psychoactive element in marijuana.
The Texas PMP is a patient care tool that can be used to inform prescribing practice and to address prescription drug misuse, diversion, and overdose. As the only statewide electronic database that stores all controlled substance information, the Texas PMP helps prescribers and pharmacists avoid potentially life-threatening drug interactions, decide when to make referrals to specialty treatment providers, and identify individuals obtaining controlled substances from multiple health care providers and pharmacies. The Texas PMP shares prescription data with 30 other states/entities, allowing prescribers and pharmacists to track prescriptions dispensed outside of Texas.
Data from the National Health and Nutrition Examination Survey and the Canadian Health Measures Survey
The PDMP Training and Technical Assistance Center (TTAC) continuously strives to keep prescription drug monitoring programs (PDMPs) and other stakeholders informed and current on the issues that concern and impact PDMPs. Legislative and regulatory change is an area TTAC monitors in order to provide an in-depth overview of PDMPs across the United States. TTAC has compiled a complete listing of all state PDMP statutes and regulations. The report is broken down by topic area (e.g., data transmitters, authorized recipients, mandatory query provisions) for each state, territory, and jurisdiction with a PDMP. The information in the report is based on the statutes and regulations in each jurisdiction and every effort has been made to ensure its accuracy. TTAC will strive to keep the information current with routine updates. The statutory and regulatory citations included in the report are current through June 30, 2019. A copy of the report can be found here: Statutes and Regulations.
Gels, creams, and pills containing cannabidiol (CBD), the non-psychoactive, potentially therapeutic compound in the cannabis plant, have proliferated at a seemingly exponential rate in the past five years.
The industry is poised to double in growth each year between now and 2024, according to cannabis consumer research firm BDS Analytics.
But CBD is still in a regulatory gray area, with the Food and Drug Administration (FDA) in the process of wading through scientific and public commentTrusted Source to refine its regulatory strategy toward CBD products.
Previously, physicians reported overdoses from these “Penalty Group 1” drugs only via phone call or by faxing a paper form to the Texas Poison Center Network.
The new electronic form replaces phone and fax reporting. It is expected to make reporting and collecting overdose data more efficient, DSHS officials said.
State law requires physicians or the person in charge of a facility in which an overdose occurs or is treated to report the overdose to the DSHS.
